ALNYLAM PHARMACEUTICALS, INC. Investing Cash Flow
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Investing Cash Flow of -$389.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$37.17M.
- ALNYLAM PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $501.11M.
- ALNYLAM PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-06-30 was -$141.38M, a 516.56% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-03-31 was $113.77M.
- ALNYLAM PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2025 was $436.33M.
- ALNYLAM PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2024 was -$116.84M.
- ALNYLAM PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2023 was -$336.35M, a 298.61% decline from fiscal 2022.
- ALNYLAM PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2022 was $169.35M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$389.00M 10-Q · filed 2026-07-30 | |||
| 2025-12-31 | -$37.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $463.94M derived: sum of 2 quarters · filed 2026-02-12 | $322.56M derived: sum of 3 quarters · filed 2026-07-30 | $436.33M 10-K · filed 2026-02-12 |
| 2025-09-30 | $501.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $359.73M derived: sum of 2 quarters · filed 2026-07-30 | $473.50M 10-Q · filed 2025-10-30 | $420.58M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | -$141.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$27.61M 10-Q · filed 2026-07-30 | -$80.52M derived: sum of 3 quarters · filed 2026-07-30 | -$110.77M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $113.77M 10-Q · filed 2025-05-01 | $60.86M derived: sum of 2 quarters · filed 2026-02-12 | $30.61M derived: sum of 3 quarters · filed 2026-02-12 | $64.55M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-12-31 | -$52.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$83.16M derived: sum of 2 quarters · filed 2026-02-12 | -$49.22M derived: sum of 3 quarters · filed 2026-02-12 | -$116.84M 10-K · filed 2026-02-12 |
| 2024-09-30 | -$30.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $3.69M derived: sum of 2 quarters · filed 2025-10-30 | -$63.93M 10-Q · filed 2025-10-30 | -$304.59M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | $33.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | -$33.68M 10-Q · filed 2025-07-31 | -$274.34M derived: sum of 3 quarters · filed 2026-02-12 | -$285.10M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | -$67.62M 10-Q · filed 2025-05-01 | -$308.28M derived: sum of 2 quarters · filed 2026-02-12 | -$319.04M derived: sum of 3 quarters · filed 2026-02-12 | -$327.75M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | -$240.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$251.42M derived: sum of 2 quarters · filed 2026-02-12 | -$260.13M derived: sum of 3 quarters · filed 2026-02-12 | -$336.35M 10-K · filed 2026-02-12 |
| 2023-09-30 | -$10.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$19.48M derived: sum of 2 quarters · filed 2024-10-31 | -$95.69M 10-Q · filed 2024-10-31 | -$235.60M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-06-30 | -$8.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$84.93M 10-Q · filed 2024-08-01 | -$224.84M derived: sum of 3 quarters · filed 2025-02-13 | $89.05M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-03-31 | -$76.22M 10-Q · filed 2024-05-02 | -$216.13M derived: sum of 2 quarters · filed 2025-02-13 | $97.76M derived: sum of 3 quarters · filed 2025-02-13 | $240.56M derived: sum of 4 quarters · filed 2025-02-13 |
| 2022-12-31 | -$139.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $173.98M derived: sum of 2 quarters · filed 2025-02-13 | $316.77M derived: sum of 3 quarters · filed 2025-02-13 | $169.35M 10-K · filed 2025-02-13 |
| 2022-09-30 | $313.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $456.68M derived: sum of 2 quarters · filed 2023-11-02 | $309.26M 10-Q · filed 2023-11-02 | -$104.14M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $142.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$4.63M 10-Q · filed 2023-08-03 | -$418.03M derived: sum of 3 quarters · filed 2024-02-15 | -$506.30M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | -$147.42M 10-Q · filed 2023-05-04 | -$560.82M derived: sum of 2 quarters · filed 2024-02-15 | -$649.10M derived: sum of 3 quarters · filed 2024-02-15 | -$492.07M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | -$413.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$501.68M derived: sum of 2 quarters · filed 2024-02-15 | -$344.65M derived: sum of 3 quarters · filed 2024-02-15 | -$273.30M 10-K · filed 2024-02-15 |
| 2021-09-30 | -$88.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $68.75M derived: sum of 2 quarters · filed 2022-10-27 | $140.10M 10-Q · filed 2022-10-27 | $42.22M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $157.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-28 | $228.38M 10-Q · filed 2022-07-28 | $130.49M derived: sum of 3 quarters · filed 2023-02-23 | $120.40M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $71.35M 10-Q · filed 2022-04-28 | -$26.54M derived: sum of 2 quarters · filed 2023-02-23 | -$36.62M derived: sum of 3 quarters · filed 2023-02-23 | -$477.85M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | -$97.89M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$107.98M derived: sum of 2 quarters · filed 2023-02-23 | -$549.21M derived: sum of 3 quarters · filed 2023-02-23 | -$435.52M 10-K · filed 2023-02-23 |
| 2020-09-30 | -$10.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | -$451.32M derived: sum of 2 quarters · filed 2021-10-28 | -$337.63M 10-Q · filed 2021-10-28 | -$558.48M derived: sum of 4 quarters · filed 2022-02-10 |
| 2020-06-30 | -$441.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | -$327.54M 10-Q · filed 2021-08-03 | -$548.39M derived: sum of 3 quarters · filed 2022-02-10 | -$558.47M derived: sum of 4 quarters · filed 2022-02-10 |
| 2020-03-31 | $113.69M 10-Q · filed 2021-04-29 | -$107.16M derived: sum of 2 quarters · filed 2022-02-10 | -$117.24M derived: sum of 3 quarters · filed 2022-02-10 | -$406.64M derived: sum of 4 quarters · filed 2022-02-10 |
| 2019-12-31 | -$220.85M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | -$230.93M derived: sum of 2 quarters · filed 2022-02-10 | -$520.33M derived: sum of 3 quarters · filed 2022-02-10 | -$417.68M 10-K · filed 2022-02-10 |
| 2019-09-30 | -$10.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$299.48M derived: sum of 2 quarters · filed 2020-11-05 | -$196.83M 10-Q · filed 2020-11-05 | $52.14M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-06-30 | -$289.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$186.75M 10-Q · filed 2020-08-06 | $62.21M derived: sum of 3 quarters · filed 2021-02-11 | $158.39M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-03-31 | $102.65M 10-Q · filed 2020-05-06 | $351.62M derived: sum of 2 quarters · filed 2021-02-11 | $447.79M derived: sum of 3 quarters · filed 2021-02-11 | $510.41M derived: sum of 4 quarters · filed 2021-02-11 |
| 2018-12-31 | $248.96M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $345.14M derived: sum of 2 quarters · filed 2021-02-11 | $407.76M derived: sum of 3 quarters · filed 2021-02-11 | $272.94M 10-K · filed 2021-02-11 |
| 2018-09-30 | $96.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $158.79M derived: sum of 2 quarters · filed 2019-10-31 | $23.98M 10-Q · filed 2019-10-31 | -$136.61M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-06-30 | $62.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$72.19M 10-Q · filed 2019-08-06 | -$232.78M derived: sum of 3 quarters · filed 2020-02-13 | -$369.96M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-03-31 | -$134.81M 10-Q · filed 2019-05-02 | -$295.40M derived: sum of 2 quarters · filed 2020-02-13 | -$432.58M derived: sum of 3 quarters · filed 2020-02-13 | |
| 2017-12-31 | -$160.59M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | -$297.77M derived: sum of 2 quarters · filed 2020-02-13 | -$290.36M 10-K · filed 2020-02-13 | |
| 2017-09-30 | -$137.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$129.77M 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | $7.41M 10-Q · filed 2018-08-02 | |||
| 2016-12-31 | $142.59M 10-K · filed 2019-02-14 | |||
| 2013-12-31 | $56.05M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20 | $53.54M derived: sum of 2 quarters · filed 2014-02-20 | $335.00K derived: sum of 3 quarters · filed 2014-02-20 | -$130.50M 10-K · filed 2014-02-20 |
| 2013-09-30 | -$2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | -$55.71M derived: sum of 2 quarters · filed 2013-11-07 | -$186.55M 10-Q · filed 2013-11-07 | -$143.04M derived: sum of 4 quarters · filed 2014-02-20 |
| 2013-06-30 | -$53.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | -$184.05M 10-Q · filed 2013-08-09 | -$140.54M derived: sum of 3 quarters · filed 2014-02-20 | -$122.68M derived: sum of 4 quarters · filed 2014-02-20 |
| 2013-03-31 | -$130.84M 10-Q · filed 2013-05-07 | -$87.33M derived: sum of 2 quarters · filed 2014-02-20 | -$69.47M derived: sum of 3 quarters · filed 2014-02-20 | -$61.87M derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-12-31 | $43.51M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20 | $61.37M derived: sum of 2 quarters · filed 2014-02-20 | $68.97M derived: sum of 3 quarters · filed 2014-02-20 | $3.37M 10-K · filed 2014-02-20 |
| 2012-09-30 | $17.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $25.45M derived: sum of 2 quarters · filed 2013-11-07 | -$40.14M 10-Q · filed 2013-11-07 | -$19.36M derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-06-30 | $7.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | -$57.99M 10-Q · filed 2013-08-09 | -$37.21M derived: sum of 3 quarters · filed 2014-02-20 | -$957.00K derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-03-31 | -$65.59M 10-Q · filed 2013-05-07 | -$44.81M derived: sum of 2 quarters · filed 2014-02-20 | -$8.56M derived: sum of 3 quarters · filed 2014-02-20 | -$5.92M derived: sum of 4 quarters · filed 2014-02-20 |
| 2011-12-31 | $20.78M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20 | $57.03M derived: sum of 2 quarters · filed 2014-02-20 | $59.67M derived: sum of 3 quarters · filed 2014-02-20 | $81.96M 10-K · filed 2014-02-20 |
| 2011-09-30 | $36.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-05 | $38.89M derived: sum of 2 quarters · filed 2012-11-05 | $61.17M 10-Q · filed 2012-11-05 | $108.75M derived: sum of 4 quarters · filed 2013-02-19 |
| 2011-06-30 | $2.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | $24.92M 10-Q · filed 2012-08-08 | $72.50M derived: sum of 3 quarters · filed 2013-02-19 | $77.19M derived: sum of 4 quarters · filed 2013-02-19 |
| 2011-03-31 | $22.29M 10-Q · filed 2012-05-03 | $69.87M derived: sum of 2 quarters · filed 2013-02-19 | $74.55M derived: sum of 3 quarters · filed 2013-02-19 | $47.59M derived: sum of 4 quarters · filed 2013-02-19 |
| 2010-12-31 | $47.58M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-19 | $52.26M derived: sum of 2 quarters · filed 2013-02-19 | $25.30M derived: sum of 3 quarters · filed 2013-02-19 | $17.84M 10-K · filed 2013-02-19 |
| 2010-09-30 | $4.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | -$22.28M derived: sum of 2 quarters · filed 2011-11-03 | -$29.74M 10-Q · filed 2011-11-03 | $25.88M derived: sum of 4 quarters · filed 2012-02-13 |
| 2010-06-30 | -$26.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-03 | -$34.42M 10-Q · filed 2011-08-03 | $21.19M derived: sum of 3 quarters · filed 2012-02-13 | -$8.76M derived: sum of 4 quarters · filed 2012-02-13 |
| 2010-03-31 | -$7.46M 10-Q · filed 2011-05-05 | $48.16M derived: sum of 2 quarters · filed 2012-02-13 | $18.20M derived: sum of 3 quarters · filed 2012-02-13 | |
| 2009-12-31 | $55.62M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-13 | $25.66M derived: sum of 2 quarters · filed 2012-02-13 | $14.43M 10-K · filed 2012-02-13 | |
| 2009-09-30 | -$29.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-04 | -$41.19M 10-Q · filed 2010-11-04 | ||
| 2009-06-30 | -$11.23M 10-Q · filed 2010-08-05 | |||
| 2008-12-31 | $17.94M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |